Cellebrite DI (NASDAQ:CLBT) Given New $26.00 Price Target at Lake Street Capital

Cellebrite DI (NASDAQ:CLBT) had its target price hoisted by Lake Street Capital from $17.00 to $26.00 in a research report report published on Friday,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Several other analysts also recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Cellebrite DI in a report on Friday. JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Craig Hallum boosted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Trading Down 5.5 %

Cellebrite DI stock opened at $20.50 on Friday. Cellebrite DI has a fifty-two week low of $9.96 and a fifty-two week high of $26.30. The firm has a 50 day moving average price of $22.58 and a 200 day moving average price of $19.10.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. As a group, equities research analysts anticipate that Cellebrite DI will post 0.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in shares of Cellebrite DI by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock worth $7,202,000 after purchasing an additional 75,092 shares during the last quarter. Telemark Asset Management LLC purchased a new stake in shares of Cellebrite DI during the 3rd quarter worth $6,736,000. Two Sigma Advisers LP lifted its position in shares of Cellebrite DI by 9.8% during the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock worth $22,584,000 after purchasing an additional 120,000 shares during the last quarter. Harbor Capital Advisors Inc. lifted its position in shares of Cellebrite DI by 65.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company’s stock worth $3,473,000 after purchasing an additional 62,320 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Cellebrite DI by 7.3% during the 3rd quarter. State Street Corp now owns 443,700 shares of the company’s stock worth $7,472,000 after purchasing an additional 30,052 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.